We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Homology Medicines Inc | NASDAQ:FIXX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.9347 | 0.8911 | 0.9293 | 0 | 01:00:00 |
“We recently closed our deal with Oxford Biomedica to form a new company that incorporates Homology’s expertise in AAV process development and manufacturing capabilities, team and GMP facility,” stated Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines. “Months ago, we made a strategic decision to find the right opportunity to leverage these internal capabilities that supported three successfully cleared INDs and our pipeline. We believe the structure of this partnership with a global leader in viral vector manufacturing is unique in allowing us to retain an ownership position in what we have built over the years. It also enables us to benefit from preferred customer access to the same high quality, innovative manufacturing capabilities and team, as well as any future value creation. In addition, the $130 million in non-dilutive capital and the resulting cost-savings from the deal significantly extends our cash runway in support of our three clinical programs and pipeline.”
Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines, added, “Initiating the pheEDIT gene editing trial was a major accomplishment as this is a novel approach to treat PKU that utilizes a different arm of our AAVHSC technology platform. Launching our juMPStart gene therapy trial for Hunter syndrome represents the first program to enter the clinic with a one-time systemic administration that is designed to address peripheral and CNS components of the disease, which is a highly differentiated approach. We will continue to work with our clinical sites and the patient communities to execute on both trials, and plan to provide program updates by year-end 2022.”
Consistent with Homology’s prior announcement of a clinical hold on its pheNIX gene therapy trial for phenylketonuria (PKU), the Company received the anticipated letter from the U.S. Food and Drug Administration (FDA) detailing the information requested for elevated liver function tests (LFTs) observed in the trial and modified clinical-mitigation measures with nothing related to Homology’s other two clinical programs or its CMC/manufacturing capability. In patients who experienced elevated LFTs, all have resolved and no hospitalizations were required. Among the risk-mitigation methods that Homology intends to propose is a new, more targeted immunosuppressive regimen that is shorter in duration and includes a T-cell inhibitor used in combination with a steroid-sparing regimen that may improve patient compliance. The Company has already incorporated this regimen into its pheEDIT gene editing trial for adults with PKU. The use of T-cell inhibitors has been shown to be effective in dampening the anticipated immune response to AAV capsids, which are commonly employed to deliver genetic medicines. Homology also noted that interest in the pheEDIT study is steadily increasing with 15 clinical sites already selected to participate, several pending site initiation visits expected shortly, and more clinical trial sites on the horizon. A program update on pheEDIT is still expected by year-end 2022.
With the additional information requested by FDA on the pheNIX trial and the planned conversion to a more specific steroid-sparing immunosuppressive regimen, Homology estimates that it will require more time to submit and receive feedback on its proposed clinical risk-mitigation strategy. This also includes time needed to amend the pheNIX study protocol. As a result, the Company now expects to provide a program update when the path forward is established with FDA.
Fourth Quarter 2021 and Recent Accomplishments
Fourth Quarter 2021 and Full Year Financial Results
Upcoming Events
About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-102, an investigational gene therapy for adults with phenylketonuria (PKU); HMI-103, a gene editing candidate for PKU; and HMI-203, an investigational gene therapy for Hunter syndrome. Additional programs focus on metachromatic leukodystrophy (MLD), paroxysmal nocturnal hemoglobinuria (PNH) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo through a gene therapy or nuclease-free gene editing modality, as well as to deliver one-time gene therapy to produce antibodies throughout the body through the GTx-mAb platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit www.homologymedicines.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including timing and expectations surrounding communications with the FDA regarding the pheNIX trial clinical hold and related updates from the Company; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our position as a leader in the development of genetic medicines; the sufficiency of our cash and cash equivalents to fund our operations; and our participation in upcoming presentations and conferences. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
HOMOLOGY MEDICINES, INC. | ||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
(in thousands) | ||||||
December 31, | ||||||
2021 | 2020 | |||||
Cash, cash equivalents and short-term investments | $ | 155,873 | $ | 217,431 | ||
Assets held for sale | 28,907 | — | ||||
Property and equipment, net | 2,252 | 37,002 | ||||
Right-of-use assets | 15,607 | 5,897 | ||||
Other assets | 9,082 | 3,407 | ||||
Total assets | $ | 211,721 | $ | 263,737 | ||
Accounts payable, accrued expenses and other liabilities | $ | 13,772 | $ | 14,525 | ||
Operating lease liabilities | 246 | 2,501 | ||||
Operating lease liabilities, net of current portion | 23,688 | 12,941 | ||||
Deferred revenue | 4,364 | 37,775 | ||||
Stockholders' equity | 169,651 | 195,995 | ||||
Total liabilities and stockholders' equity | $ | 211,721 | $ | 263,737 |
HOMOLOGY MEDICINES, INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(in thousands, except share and per share amounts) | ||||||||||||||||
For the Three Months Ended December 31, | For the Year Ended December 31, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
(unaudited) | ||||||||||||||||
Collaboration revenue | $ | 802 | $ | 980 | $ | 33,971 | $ | 2,702 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 23,646 | 23,195 | 93,085 | 100,392 | ||||||||||||
General and administrative | 10,781 | 7,587 | 36,835 | 32,573 | ||||||||||||
Total operating expenses | 34,427 | 30,782 | 129,920 | 132,965 | ||||||||||||
Loss from operations | (33,625 | ) | (29,802 | ) | (95,949 | ) | (130,263 | ) | ||||||||
Other income: | ||||||||||||||||
Interest income | 42 | 11 | 185 | 1,569 | ||||||||||||
Total other income | 42 | 11 | 185 | 1,569 | ||||||||||||
Net loss | $ | (33,583 | ) | $ | (29,791 | ) | $ | (95,764 | ) | $ | (128,694 | ) | ||||
Net loss per share-basic and diluted | $ | (0.59 | ) | $ | (0.62 | ) | $ | (1.73 | ) | $ | (2.80 | ) | ||||
Weighted-average common shares outstanding-basic and diluted | 57,150,079 | 48,112,174 | 55,283,318 | 45,910,787 |
Company Contacts:Theresa McNeelyChief Communications Officer and Patient Advocatetmcneely@homologymedicines.com781-301-7277
Media Contact:Cara Mayfield Vice President, Patient Advocacy and Corporate Communications cmayfield@homologymedicines.com 781-691-3510
1 Year Homology Medicines Chart |
1 Month Homology Medicines Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions